David A Quigley
Overview
Explore the profile of David A Quigley including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
67
Citations
2281
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Moreno T, Magana J, Quigley D
Bioinformatics
. 2023 Aug;
39(8).
PMID: 37584701
Summary: Resistance to two classes of FDA-approved therapies that target DNA repair-deficient tumors is caused by mutations that restore the tumor cell's DNA repair function. Identifying these "reversion" mutations currently...
12.
Chappidi M, Sjostrom M, Greenland N, Cowan J, Baskin A, Shee K, et al.
Eur Urol Oncol
. 2023 Jul;
7(2):222-230.
PMID: 37474400
Background: Prostate cancers featuring an expansile cribriform (EC) pattern are associated with worse clinical outcomes following radical prostatectomy (RP). However, studies of the genomic characteristics of Gleason pattern 4 subtypes...
13.
Lundberg A, Zhang M, Aggarwal R, Li H, Zhang L, Foye A, et al.
Cancer Res
. 2023 Jun;
83(16):2763-2774.
PMID: 37289025
Significance: Comprehensive characterization of the five subtypes of metastatic castration-resistant prostate cancer identified transcription factors that drive each subtype and showed that the double-negative subtype has the worst prognosis.
14.
Sayar E, Patel R, Coleman I, Roudier M, Zhang A, Mustafi P, et al.
JCI Insight
. 2023 Feb;
8(7).
PMID: 36821396
Prostate-specific membrane antigen (PSMA) is an important cell surface target in prostate cancer. There are limited data on the heterogeneity of PSMA tissue expression in metastatic castration-resistant prostate cancer (mCRPC)....
15.
OLeary P, Chen H, Doruk Y, Williamson T, Polacco B, McNeal A, et al.
Cancer Res
. 2022 Oct;
82(21):3950-3961.
PMID: 36273492
Significance: Loss of NMD proteins promotes resistance to ATR inhibitors in gastric cancer cells, which may provide a combination of therapeutic targets and biomarkers to improve the clinical utility of...
16.
Feng E, Rydzewski N, Zhang M, Lundberg A, Bootsma M, Helzer K, et al.
Clin Cancer Res
. 2022 Oct;
28(24):5396-5404.
PMID: 36260524
Purpose: Although numerous biology-driven subtypes have been described previously in metastatic castration-resistant prostate cancer (mCRPC), unsupervised molecular subtyping based on gene expression has been less studied, especially using large cohorts....
17.
Sjostrom M, Zhao S, Levy S, Zhang M, Ning Y, Shrestha R, et al.
Cancer Res
. 2022 Oct;
82(21):3888-3902.
PMID: 36251389
Significance: In prostate cancer, 5-hydroxymethylcytosine delineates oncogene activation and stage-specific cell states and can be analyzed in liquid biopsies to detect cancer phenotypes. See related article by Wu and Attard,...
18.
Westbrook T, Guan X, Rodansky E, Flores D, Liu C, Udager A, et al.
Nat Commun
. 2022 Sep;
13(1):5345.
PMID: 36109521
The androgen receptor (AR) signaling inhibitor enzalutamide (enza) is one of the principal treatments for metastatic castration-resistant prostate cancer (CRPC). Several emergent enza clinical resistance mechanisms have been described, including...
19.
Zhang M, Moreno-Rodriguez T, Quigley D
Cancer Discov
. 2022 Sep;
12(9):2017-2019.
PMID: 36052502
Prostate tumors can develop resistance to androgen receptor (AR)-targeted therapies through treatment-induced changes in transcription factor activity that promote transcriptional and morphologic features of a neuroendocrine lineage. This study identifies...
20.
Herberts C, Annala M, Sipola J, Ng S, Chen X, Nurminen A, et al.
Nature
. 2022 Jul;
608(7921):199-208.
PMID: 35859180
Circulating tumour DNA (ctDNA) in blood plasma is an emerging tool for clinical cancer genotyping and longitudinal disease monitoring. However, owing to past emphasis on targeted and low-resolution profiling approaches,...